- Home
- TERN vs TNGX Comparison
TERN vs TNGX Comparison
Compare TERN & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- TNGX
- Stock Information
- Founded
- TERN 2017
- TNGX 2014
- Country
- TERN United States
- TNGX United States
- Employees
- TERN N/A
- TNGX N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- TNGX Health Care
- Exchange
- TERN Nasdaq
- TNGX Nasdaq
- Market Cap
- TERN 298.1M
- TNGX 317.4M
- IPO Year
- TERN 2021
- TNGX N/A
- Fundamental
- Price
- TERN $2.49
- TNGX $1.37
- Analyst Decision
- TERN Buy
- TNGX Strong Buy
- Analyst Count
- TERN 5
- TNGX 7
- Target Price
- TERN $18.38
- TNGX $12.33
- AVG Volume (30 Days)
- TERN 1.0M
- TNGX 782.4K
- Earning Date
- TERN 05-12-2025
- TNGX 05-07-2025
- Dividend Yield
- TERN N/A
- TNGX N/A
- EPS Growth
- TERN N/A
- TNGX N/A
- EPS
- TERN N/A
- TNGX N/A
- Revenue
- TERN N/A
- TNGX $42,069,000.00
- Revenue This Year
- TERN N/A
- TNGX N/A
- Revenue Next Year
- TERN N/A
- TNGX N/A
- P/E Ratio
- TERN N/A
- TNGX N/A
- Revenue Growth
- TERN N/A
- TNGX 15.17
- 52 Week Low
- TERN $2.46
- TNGX $1.24
- 52 Week High
- TERN $11.40
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- TERN 25.94
- TNGX 29.83
- Support Level
- TERN $3.07
- TNGX $1.48
- Resistance Level
- TERN $3.72
- TNGX $1.66
- Average True Range (ATR)
- TERN 0.22
- TNGX 0.15
- MACD
- TERN -0.04
- TNGX -0.02
- Stochastic Oscillator
- TERN 2.38
- TNGX 16.25
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.